MYOMYOHealthcare · Medical Devices

MYO Stock Forecast: Myomo, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.81
−3.45% on the day

The median 12-month analyst price target for Myomo, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 62 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$32.5M
Ticker Nerd rank
62/ 100
Median analyst target
$3.00
Analysts covering
5
Revenue$11.7M+21.3% y/y
Operating income−$2.3M
Net income−$4.0M
Free cash flow−$2.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−34.1%
1M
−35.6%
YTD
−10.9%
1Y
+12.6%
From 52W high
−56.4%
From 52W low
+26.7%
$0.64
$1.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Myomo, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
62/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
86
Quality
75
Revisions
65
Growth
63
Value
45
Momentum
39
Volatility
12
Issuance
11

Accruals (86): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MYO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MYO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26MYOHigh $10.50Median $3.00Low $1.70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$1.70
Low
$3.00
Median
$10.50
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Aug 2026Ascendiant CapitalMaintainsBuy—
8 June 2026Ascendiant CapitalMaintainsBuy—
21 Nov 2025Ascendiant CapitalMaintainsBuy—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
12 Aug 2025HC Wainwright & Co.MaintainsBuy—
23 June 2025Craig-HallumMaintainsBuy—
5 June 2025Ascendiant CapitalMaintainsBuy—
8 May 2025Craig-HallumMaintainsBuy—
17 Mar 2025Ascendiant CapitalMaintainsBuy—
12 Mar 2025HC Wainwright & Co.MaintainsBuy—
11 Mar 2025Craig-HallumMaintainsBuy—
13 Dec 2024Craig-HallumMaintainsBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy$7.50
12 Nov 2024Ascendiant CapitalMaintainsBuy—
19 Aug 2024Ascendiant CapitalMaintainsBuy—
12 Aug 2024HC Wainwright & Co.MaintainsBuy—
31 July 2024Craig-HallumInitiatesBuy—
9 July 2024Lake StreetMaintainsBuy—
9 May 2024HC Wainwright & Co.ReiteratesBuy—
15 Dec 2023HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MYO.

Market Radar

This page is one stock. Monday covers all of them.

MYO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MYO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Myomo, Inc. returned +12.6% against +6.9% for the S&P 500, dividends included.

MYO vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26MYOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MYO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.7×

Cheaper than 72% of US stocks

Price / book
11.8×

Cheaper than 6% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
22.2%

Higher than 72% of US stocks

Earnings growth (YoY)
—
Gross margin
72.1%

Higher than 84% of US stocks

Operating margin
−21.8%

Higher than 22% of US stocks

Net margin
−33.1%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−173.5%

Higher than 8% of US stocks

Return on assets
−18.2%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Myomo, Inc. has a market value of $32.5M and an enterprise value of $42.0M.

  • Revenue in the twelve months to 30 June 2026: $43.3M. The latest quarter grew 21.3% year on year.

  • Net income over the same four quarters: −$14.5M, a −33.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.34.

  • Free cash flow in the twelve months to 30 June 2026: −$9.1M.

  • Shares outstanding: 39.5M.

  • Myomo, Inc. employs 194 people — $223K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

MYO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MYOMyomo, Inc.$32.5M62
TELATELA Bio, Inc.$31.1M36
MDAISpectral AI, Inc.$33.5M26
XTNTXtant Medical Holdings, Inc.$29.5M51
NSYSNortech Systems, Inc.$29.4M82
NSPRInspireMD, Inc.$29.2M73
RPIDRapid Micro Biosystems, Inc.$36.6M36

Take a look at MYO’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Myomo, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MYO

What is the MYO stock price forecast for 2026-2027?

The median 12-month analyst price target for Myomo, Inc. is $3, with estimates ranging from $1.7 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MYO stock a buy right now?

Of the 5 analysts covering Myomo, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Myomo, Inc. 62 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MYO?

As at 21 Nov 2026, Myomo, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (86 of 100).

Will MYO stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $3, and Ticker Nerd's factor model ranks Myomo, Inc. 62 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MYO stock forecast for 2030?

No analyst covering Myomo, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MYO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.7 to $11 over the next 12 months.

How has MYO stock performed over the past year?

Myomo, Inc. returned +12.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Myomo, Inc. do?

Myomo Inc. is a medical robotics company that develops and markets myoelectric orthotic devices for people with neuromuscular disorders and upper-limb paralysis. Its flagship MyoPro product line is a powered arm brace designed to support weakened or paralyzed arms and hands by detecting the user’s own muscle signals through non-invasive sensors.

Company

About Myomo, Inc.

Myomo Inc. is a medical robotics company that develops and markets myoelectric orthotic devices for people with neuromuscular disorders and upper-limb paralysis. Its flagship MyoPro product line is a powered arm brace designed to support weakened or paralyzed arms and hands by detecting the user’s own muscle signals through non-invasive sensors. The company serves patients recovering from or living with conditions such as stroke, spinal cord injury, brachial plexus injury, traumatic brain injury, ALS, and multiple sclerosis. Myomo Inc. sells its devices through orthotics and prosthetics providers, direct clinical and insurance-based channels, the Veterans Administration, and selected distributors in the United States and international markets. The company focuses on restoring upper-limb function, supporting daily activities, and improving mobility for individuals with neurological and muscular impairments.

CEO Mr. Paul R. Gudonis · 194 employees · United States · https://myomo.com